Freestone Capital Holdings LLC lifted its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON – Free Report) by 127.1% in the first quarter, HoldingsChannel reports. The firm owned 2,487 shares of the biotechnology company’s stock after acquiring an additional 1,392 shares during the period. Freestone Capital Holdings LLC’s holdings in Axon Enterprise were worth $778,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also recently bought and sold shares of AXON. Dynamic Advisor Solutions LLC bought a new position in shares of Axon Enterprise during the fourth quarter worth about $226,000. BKM Wealth Management LLC bought a new position in shares of Axon Enterprise during the fourth quarter worth about $32,000. Brookstone Capital Management bought a new position in shares of Axon Enterprise during the fourth quarter worth about $206,000. HB Wealth Management LLC lifted its position in shares of Axon Enterprise by 3.9% during the fourth quarter. HB Wealth Management LLC now owns 1,139 shares of the biotechnology company’s stock worth $294,000 after purchasing an additional 43 shares during the last quarter. Finally, Raymond James & Associates lifted its position in shares of Axon Enterprise by 32.8% during the fourth quarter. Raymond James & Associates now owns 83,655 shares of the biotechnology company’s stock worth $21,611,000 after purchasing an additional 20,654 shares during the last quarter. 79.08% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling
In related news, Director Julie A. Cullivan sold 993 shares of Axon Enterprise stock in a transaction on Friday, May 31st. The shares were sold at an average price of $281.72, for a total value of $279,747.96. Following the transaction, the director now owns 4,553 shares in the company, valued at approximately $1,282,671.16. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, Director Julie A. Cullivan sold 993 shares of Axon Enterprise stock in a transaction dated Friday, May 31st. The shares were sold at an average price of $281.72, for a total transaction of $279,747.96. Following the sale, the director now directly owns 4,553 shares in the company, valued at approximately $1,282,671.16. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Julie A. Cullivan sold 478 shares of Axon Enterprise stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $286.04, for a total transaction of $136,727.12. Following the sale, the director now owns 5,546 shares in the company, valued at $1,586,377.84. The disclosure for this sale can be found here. Insiders have sold 89,447 shares of company stock worth $27,684,677 in the last quarter. 6.10% of the stock is currently owned by company insiders.
Analyst Upgrades and Downgrades
Get Our Latest Research Report on AXON
Axon Enterprise Stock Up 0.0 %
Shares of Axon Enterprise stock traded up $0.12 during midday trading on Friday, reaching $310.93. 166,577 shares of the company’s stock traded hands, compared to its average volume of 487,389. The company has a market cap of $23.47 billion, a price-to-earnings ratio of 90.88, a price-to-earnings-growth ratio of 7.06 and a beta of 0.95. The company’s 50 day simple moving average is $294.06 and its 200 day simple moving average is $291.32. The company has a debt-to-equity ratio of 0.37, a quick ratio of 2.55 and a current ratio of 2.91. Axon Enterprise, Inc. has a 52 week low of $175.37 and a 52 week high of $329.87.
Axon Enterprise (NASDAQ:AXON – Get Free Report) last announced its earnings results on Friday, May 10th. The biotechnology company reported $1.15 EPS for the quarter, topping the consensus estimate of $0.95 by $0.20. The firm had revenue of $460.74 million for the quarter, compared to the consensus estimate of $441.57 million. Axon Enterprise had a net margin of 15.60% and a return on equity of 11.71%. The business’s quarterly revenue was up 34.3% on a year-over-year basis. During the same quarter last year, the firm posted $0.51 EPS. Equities analysts expect that Axon Enterprise, Inc. will post 2.35 earnings per share for the current fiscal year.
Axon Enterprise Profile
Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.
See Also
- Five stocks we like better than Axon Enterprise
- What Does a Stock Split Mean?
- 3M Surprises and Rebound Accelerates: It Isn’t Too Late To Get In
- The How and Why of Investing in Gold Stocks
- Skechers Stock Shows Strength Among Consumer Discretionary Sector
- Earnings Per Share Calculator: How to Calculate EPS
- Tech Stocks Tumble, These Stocks Present Buying Opportunity
Want to see what other hedge funds are holding AXON? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Axon Enterprise, Inc. (NASDAQ:AXON – Free Report).
Receive News & Ratings for Axon Enterprise Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axon Enterprise and related companies with MarketBeat.com's FREE daily email newsletter.